, /PRNewswire/ -- , a next-generation molecular diagnostics company, announced today that it has raised in an oversubscribed, upsized Series D round. The financing was led by Premji Invest, with significant participation by another incoming investor, Neuberger Berman, as well as by prominent existing investors, including Adam Street Partners, Baillie Gifford, Hummingbird Ventures, Civilization Ventures, Libertus Capital, and Fifty Years. The funding will be used for expanding and scaling BillionToOne's prenatal and oncology businesses.
BillionToOne's unique technology, Quantitative Counting TemplatesTM, QCTsTM, enables counting DNA molecules with single base-pair precision, and it has allowed the company to develop truly differentiated tests that redefine the possibilities of molecular diagnostics. Over patients have received BillionToOne tests to date, and BillionToOne has grown from to ARR in the last ~4 years. UNITY Fetal Risk Screen is the first-and-only prenatal test of its kind.
The test leverages fetal cell-free DNA to provide direct insights into fetal risk for aneuploidies and common recessively inherited conditions, such as sickle cell disease, spinal muscular atrophy, and cystic fibrosis, without requiring a blood sample from the male partner or amniocentesis. BillionToOne's complementary oncology liquid biopsy products, Northstar Select® and Northstar Response®, enable clinicians to select the right therapies and monitor patients' responses to therapies, particu.
